Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

Abstract This prospective cohort study reports aneuploidy score by mFast-SeqS as a strong prognostic marker in MBC patients. mFAST-SeqS is an affordable and easily implementable method for the assessment of total ctDNA levels and, as such, provides an alternative prognostic tool. One mixed cohort (c...

Full description

Bibliographic Details
Main Authors: Noortje Verschoor, Vanja de Weerd, Mai N. Van, Jaco Kraan, Marcel Smid, Joan B. Heijns, Jan C. Drooger, Johanna M. Zuetenhorst, Annemieke van der Padt-Pruijsten, Agnes Jager, Stefan Sleijfer, John W. M. Martens, Saskia M. Wilting
Format: Article
Language:English
Published: Nature Portfolio 2023-07-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00563-w

Internet

https://doi.org/10.1038/s41523-023-00563-w

Similar Items